Regeneron: Driven by Science
For over 25 years, Regeneron's vision has been to build an innovative company that consistently brings new medicines to patients with serious diseases.
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients06/06/16
TARRYTOWN, N.Y. and PARIS, June 6, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with...
Citi Innovation & Technology in Biotech Series: Regeneron Pharmaceuticals06/24/16 at 9:00 AM ET
2016 Annual Meeting of Shareholders06/10/16 at 10:30 AM ET